Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Recruiting
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Recruiting
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Not Yet Recruiting
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Coming Soon
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium

Jan 14, 2019

Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline

Dec 6, 2018

Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors

Dec 3, 2018

Rexahn Pharmaceuticals Announces Leadership Transition

Nov 14, 2018

Rexahn Reports Third Quarter 2018 Financial Results

Nov 5, 2018

Rexahn Announces $7.5 Million Registered Direct Offering

Oct 17, 2018

Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data from Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer

Oct 2, 2018

Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium

Sep 18, 2018

Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Aug 30, 2018

Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

Aug 21, 2018
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...33
    Ocuphire Pharma, Inc.
    © Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use